ArticleCurrent microbiology2025
Screening of Secondary Metabolites with Synergistic Potential Associated with Amoxicillin: An In Vitro and In Silico Approach.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advancement of Antimicrobial Resistance (AMR) and the lack of effective treatments demand the development of new drugs to combat resistant bacteria. Plants, in turn, produce various Secondary Metabolites (SMs) with diverse molecular structures, which are promising therapeutic alternatives. This study aims to evaluate the potential of 13 plant derived SMs in modulating bacterial resistance to amoxicillin (AMO), and to investigate the mechanisms of action against Staphylococcus aureus (ATCC 29213) and Klebsiella pneumoniae (UFPDA 396) using Molecular Docking (MD) simulations. Among the tested SMs, p-Cymene (CYM) showed the best activity against S. aureus, with a Minimum Inhibitory Concentration (MIC) of 512 µg/mL, while Eugenol (EUG) was most effective against K. pneumoniae, with an MIC of 1024 µg/mL. In resistance modulation assays using the checkerboard method, SMs including EUG, CYM, α-pinene (APN), β-pinene (BPN), Geraniol (GER), Linalool (LNL), and Myrcene (MYR) exhibited synergistic effects when combined with AMO, with Fractional Inhibitory Concentration Index (FICI) values ranging from 0.1 to 0.5. Additionally, both the SMs and AMO, as well as their synergistic combinations, were docked to molecular targets associated with resistance and virulence in S. aureus and K. pneumoniae. The drug-protein complexes showed favorable interaction energies, confirming that the binding free energy of the synergistic combinations was superior to that of the individual compounds. Overall, the most significant differences in activity between combined and isolated treatments were observed for MurD in S. aureus and SidA in K. pneumoniae. These findings suggest that SMs may serve as potential candidates for the development of synergistic or additive molecules to be used alongside conventional antibiotics, representing a promising strategy to mitigate AMR and offer viable and effective therapeutic alternatives.
Indexed as
Identifiers
41204985What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.